These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 8874986)

  • 21. Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.
    Yee HS; Fong NT
    Ann Pharmacother; 1998 Oct; 32(10):1030-43. PubMed ID: 9793596
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evidence for the benefit of early intervention with pravastatin for secondary prevention of cardiovascular events.
    Arntz HR
    Atherosclerosis; 1999 Sep; 147 Suppl 1():S17-21. PubMed ID: 10575058
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pravastatin, lipids, and atherosclerosis in the carotid arteries: design features of a clinical trial with carotid atherosclerosis outcome.
    Crouse JR; Byington RP; Bond MG; Espeland MA; Sprinkle JW; McGovern M; Furberg CD
    Control Clin Trials; 1992 Dec; 13(6):495-506. PubMed ID: 1334821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparative effects of two HMG-CoA reductase inhibitors (lovastatin and pravastatin) on serum lipids and lipoproteins.
    Richter WO; Jacob BG; Schwandt P
    Int J Tissue React; 1991; 13(2):107-10. PubMed ID: 1955291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.
    de Groot E; Jukema JW; van Boven AJ; Reiber JH; Zwinderman AH; Lie KI; Ackerstaff RA; Bruschke AV
    Am J Cardiol; 1995 Sep; 76(9):40C-46C. PubMed ID: 7572685
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A clinical focus on statins.
    Auer J; Eber B
    Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pluripotential mechanisms of cardioprotection with HMG-CoA reductase inhibitor therapy.
    Rosenson RS
    Am J Cardiovasc Drugs; 2001; 1(6):411-20. PubMed ID: 14728000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin.
    Gotto AM
    Am J Cardiol; 2005 Sep; 96(5A):34F-38F. PubMed ID: 16126021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.
    Furberg CD; Adams HP; Applegate WB; Byington RP; Espeland MA; Hartwell T; Hunninghake DB; Lefkowitz DS; Probstfield J; Riley WA
    Circulation; 1994 Oct; 90(4):1679-87. PubMed ID: 7734010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statins in the 21st century: end of the simple story?
    Doggrell SA
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1755-66. PubMed ID: 11772284
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of eicosapentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS).
    Yokoyama M; Origasa H;
    Am Heart J; 2003 Oct; 146(4):613-20. PubMed ID: 14564313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation.
    Pitt B; Mancini GB; Ellis SG; Rosman HS; Park JS; McGovern ME
    J Am Coll Cardiol; 1995 Nov; 26(5):1133-9. PubMed ID: 7594023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pravastatin. A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.
    Haria M; McTavish D
    Drugs; 1997 Feb; 53(2):299-336. PubMed ID: 9028747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Angiographic intervention trial using HMG CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma in West Japan (ATHEROMA study): rationale, design and baseline.
    Kawaguchi A; Mitsudo K; Nobuyoshi M; Minamino R; Hayasaki K; Nakashima M; Yamamoto A;
    J Cardiovasc Risk; 2002 Feb; 9(1):7-16. PubMed ID: 11984212
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
    Kleinveld HA; Demacker PN; De Haan AF; Stalenhoef AF
    Eur J Clin Invest; 1993 May; 23(5):289-95. PubMed ID: 8354335
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.
    Duplaga BA
    Ann Pharmacother; 1999 Nov; 33(11):1224-7. PubMed ID: 10573325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.
    Nicholls SJ; Tuzcu EM; Sipahi I; Grasso AW; Schoenhagen P; Hu T; Wolski K; Crowe T; Desai MY; Hazen SL; Kapadia SR; Nissen SE
    JAMA; 2007 Feb; 297(5):499-508. PubMed ID: 17284700
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimal goals for statin use in patients with coronary artery disease.
    Ray KK; Cannon CP
    Curr Opin Cardiol; 2005 Nov; 20(6):525-9. PubMed ID: 16234625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.